MedTrace Logo

REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression

NCT02584465 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2023-09-06

No results posted yet for this study

Summary

The objective of this randomized phase II is to evaluate the benefit of regorafenib for ovarian patients who reported a confirmed elevated CA-125 level under surveillance or bevacizumab, compared with tamoxifen.

Conditions

  • Ovarian Carcinoma

Interventions

DRUG

Tamoxifen

Tamoxifen: 40 mg/day

DRUG

Regorafenib

Stivarga; 120mg/day

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • ARCAGY/ GINECO GROUP

    lead OTHER

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-28
Primary Completion
2021-09-19
Completion
2021-09-19

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02584465 on ClinicalTrials.gov